Desiree Ortiz-Cruz, MD
Neurology · Bloomington, INNPI 1447355201
Payments from drug & device makers
Across 224 payments — averaging $2213.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$490K
- AbbVie$699
- UCB, Inc.$539
- AstraZeneca$473
- Novartis$367
- SK Life Science, Inc.$350
- plus $3K from 28 others
Across 6 payments — averaging $31,057 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$186K
What the payments were for
- Speaking & faculty fees$1252%
- Food & beverage$5,62298%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $489,958 |
| AbbVie | 28 | $699 |
| UCB, Inc. | 21 | $539 |
| AstraZeneca | 9 | $473 |
| Novartis | 11 | $367 |
| SK Life Science, Inc. | 14 | $350 |
| Teva Pharmaceuticals USA, Inc. | 8 | $287 |
| Neurocrine Biosciences, Inc. | 15 | $273 |
| Biogen | 8 | $268 |
| Amneal Pharmaceuticals LLC | 3 | $227 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $223 |
| Lundbeck LLC | 7 | $217 |
| Amgen | 2 | $187 |
| Bristol Myers Squibb | 10 | $182 |
| Impel Pharmaceuticals Inc. | 5 | $164 |
| EMD Serono, Inc. | 4 | $162 |
| Lilly USA, LLC | 6 | $160 |
| Pfizer | 9 | $160 |
| Eisai Inc. | 7 | $142 |
| Acadia Pharmaceuticals Inc | 7 | $130 |
| Argenx US, Inc. | 4 | $108 |
| Merz Pharmaceuticals, LLC | 2 | $66 |
| Corium, LLC | 3 | $61 |
| GE HealthCare | 5 | $60 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 2 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$495,717 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 92 | $116,953 |
| UbrelvyUbrogepant | 17 | $21,668 |
| BriviactBrivaracetam | 12 | $14,867 |
| QuliptaAtogepant | 13 | $13,924 |
| Memantine Hcl | 419 | $7,313 |
| EliquisApixaban | 12 | $6,675 |
| Galantamine Hbr | 122 | $5,696 |
| Atomoxetine Hcl | 14 | $5,159 |
| Levetiracetam | 93 | $2,799 |
| Pyridostigmine Bromide | 25 | $2,471 |
| Lamotrigine ErLamotrigine | 18 | $1,831 |
| Lacosamide | 18 | $1,482 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 60 | $1,351 |
| Ropinirole Hcl | 32 | $1,337 |
| Duloxetine Hcl | 62 | $1,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $160 | $123,628104 claims |
| AbbVieUbrelvy, Qulipta | $699 | $35,59230 claims |
| UCB, Inc.Briviact | $539 | $14,86712 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $227 | $2,47125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.
Other neurology in Bloomington
- Sharisse StephensonBloomington$55K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
- Alexandru BarboiIndianapolis$1.9M
- William ConteMerrillville$1.7M
- James StevensFort Wayne$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.